Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12220088 | 0.84 | TBXAS1 (0.50) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL14898388 | 0.84 | TBXAS1 (0.50) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL13934329 | 0.84 | TBXAS1 (0.50) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL890153 | 0.82 | CYP3A4 (0.41) | KMT2ACYP1A2CYP3A4CYP2C9LMNA | |
| SCHEMBL19042806 | 0.82 | MEN1 (0.59) | PKMKMT2ACYP1A2 | |
| SCHEMBL13827709 | 0.82 | MEN1 (0.59) | PKMKMT2ACYP1A2 | |
| SCHEMBL14537027 | 0.81 | TBXAS1 (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL22147478 | 0.81 | TBXAS1 (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL14864793 | 0.79 | NLRP3 (0.48) | FDPSPKMKMT2ANAPRTTBXAS1 | |
| SCHEMBL19072128 | 0.77 | FDPS (0.56) | FDPSPKMKMT2ANAPRTTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | FDPS 331/4885PKM 2497/4885KMT2A 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.